OASM - Oasmia Pharmaceutical AB: Swedish Company Targeting Ovarian Cancer But Doesn't Impress
Oasmia Pharmaceutical AB (OASM) is a Swedish company which is very diversified both geographically and in target patients. The company develops oncology drugs for both human and animal patients. Originating in 1998, they have offices in Moscow, Hong Kong, and the US, and their first therapies were initially approved in Russia (CEO is Julian Aleksov). Their technology platform is "a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents."
The platform
The company's XR17 is a vitamin-based drug delivery system on which